Karl Miran (@KarlMiran) header
Karl Miran (@KarlMiran) profile picture

45 years in education: 19 yrs college coach & 26 yrs high school coach, teacher, administrator Currently VP & Advocacy Captain NJ - HDSA

North Plainfield, NJ
Joined July 2011
Photo by Karl Miran (@KarlMiran)Photo by Karl Miran (@KarlMiran)Photo by Karl Miran (@KarlMiran)Photo by Karl Miran (@KarlMiran)Photo by Karl Miran (@KarlMiran)Photo by Karl Miran (@KarlMiran)Photo by Karl Miran (@KarlMiran)
Their season continues!
14
Karl Miran retweeted
Replying to @mahesh_shenai
@mahesh_shenai, Although we have never met, I addressed Dr. Mallika Mundkur at the @FDA's CNPV public meeting, whom I understand is your wife. After reading nearly 20 of your posts concerning Huntington’s disease (HD) and AMT-130, I have to ask: Are you evaluating the totality of the evidence, or predominantly searching for reasons to discount it? You repeatedly express hope that you will someday treat Huntington’s disease patients. But how much direct experience have you had with our community? Have you spent meaningful time with symptomatic patients across disease stages, witnessed their progressive neurological decline, or spoken with families about their risk tolerance? I ask because I have. HD has devastated three generations of my family. My grandmother died after years of suffering. Her chorea was so severe that she wore padded mittens for nearly four years to prevent her involuntary movements from dislodging her feeding tube. I was nearly my daughter’s age when my grandmother developed symptoms. Now both my daughter and son are watching their grandfather and aunt experience the same disease. My father is in the middle stages of Huntington’s disease, while my aunt is further along in its devastating progression. As a mother, I live with the painful reality that my children may one day witness this same deterioration in me—or, even more heartbreaking, experience it themselves. What I witnessed as a little girl, my children are witnessing today. Different generations, the same devastating cycle we are desperately trying to break. The psychological consequences are equally profound. A fellow Michigander and HD advocate recently lost her father to suicide. Another Michigan chapter board member nearly lost her niece, and several HD friends have lost loved ones to suicide. Suicide risk among people with Huntington’s disease is substantially higher than in the general population. Why? Imagine caring for someone you love while witnessing years of relentless neurological deterioration, all while knowing you could face the same fate. And even if you escape inheriting the mutation, you may carry the lifelong burden of survivor’s guilt as those you love continue to suffer. This is the profound, multigenerational trauma of Huntington’s disease. More than 40,000 Americans live with HD, and over 200,000 are at risk. Those figures do not include the countless caregivers and relatives whose lives are also affected. Your anecdote about a surgeon with another movement disorder reinventing his professional life was particularly revealing. When I read it, I immediately questioned your firsthand understanding of HD. HD does not afford patients the luxury of simply reinventing their lives. It progressively damages the brain circuits responsible for cognition, judgment, behavior, movement, and independence. Symptoms can worsen over 10–25 years, gradually taking away the ability to work, communicate, maintain relationships, swallow, walk, talk, and care for oneself. The ability to reinvent one's life requires precisely the neurological capacities HD progressively destroys. HD takes away the ability to meaningfully participate in life altogether. The 2024 HD Symptoms and Treatment Impact Survey found that nearly three-quarters of respondents would accept treatment risks for five years without progression, while approximately 35% would accept risks for even three years. Three more years raising children. Five more years working, communicating, remembering, and living independently. More birthdays, graduations, and time with family. Then consider the economic consequences of inaction. Over 10–25 years, HD families will face neurologists, psychiatrists, hospitalizations, expensive chorea and psychiatric medications, physical and occupational therapy, speech and swallowing therapy, mobility equipment, home modifications, specialized residential care, and eventually around-the-clock assistance. HD removes two people from the workforce: the patient and the family member who becomes their caregiver. Families lose wages, insurance benefits, retirement savings, and years of financial security. Many conventional care facilities lack the specialized neurological and behavioral resources required for HD, leaving families with limited options. These costs accumulate across households, employers, Medicare, Medicaid, disability programs, and society. When evaluating the risks and costs of treatment, why is the cost of inaction so often treated as though it were zero? If AMT-130 meaningfully preserves independence, the potential economic and societal benefits deserve consideration. You have described yourself as one of approximately 80 U.S. neurosurgeons with expertise relevant to this procedure. If AMT-130 does not meet your personal threshold for clinical adoption, that is your judgment. But your threshold is not the FDA's regulatory standard, nor should it determine the choices available to every informed patient and qualified physician. Other neurosurgeons may recognize the broader significance of this investigational gene therapy. If its clinical benefits are confirmed, AMT-130 could help transform how we approach inherited neurodegenerative disorders beyond HD. Regarding surgical risk, stereotactic neurosurgery has been performed in humans since 1947. Trial experience suggests the procedure has generally been tolerated. But the question is not whether neurosurgery carries risk. It does. The question is whether those risks are acceptable relative to the potential benefit for patients facing a progressive, fatal disease without an approved disease-modifying treatment. Your professional risks and our personal risks may look entirely different. For you, this is a discussion of procedural complications, evidence, and professional responsibility. For us, it is progressive neurological deterioration, dependency, and premature death. The reported AMT-130 findings, including favorable Total Functional Capacity trajectories compared with external controls, deserve serious consideration. TFC measures employment, financial management, domestic responsibilities, daily living, and care requirements. It measures the independence HD progressively takes away. Scientific skepticism is essential, but it must be applied symmetrically. Our community has also been wounded by regulatory rhetoric. @VPrasadMDMPH, your wife’s former boss, recently compared patients pursuing unproven treatments to a drowning person reaching for a blade. Regardless of the intended scientific warning, such language risks reducing informed, deeply personal benefit-risk decisions to acts of desperation, overlooking the devastating consequences patients and families face without treatment. Our willingness to accept uncertainty is not desperation. It reflects a rational understanding of what HD will otherwise take from us. Imagine watching someone you love progressively lose the ability to think, communicate, walk, swallow, or even recognize the people they love most. Now imagine living with the knowledge that the same devastating disease could one day affect you, your children, your siblings, or generations of your extended family. This is the reality of Huntington’s disease. What would a few additional years together mean? What would you do to break the cycle? I am not asking you to abandon scientific standards. I am asking you to recognize that the consequences of waiting are as real as the risks of treatment. The absence of treatment is not the absence of risk. It is continued disease progression, escalating dependency, enormous psychological and economic suffering, and irreversible neurological loss. You may see an investigational neurosurgical procedure that has not met your preferred evidentiary threshold. We see a potential opportunity to preserve the ability to think, communicate, work, love, and remain present in our families' lives. We are asking for scientific judgment that accounts for the full reality of Huntington’s disease. P.S. Go Blue! 〽️💙💛 #HuntingtonsDisease #RareDisease
14
43
9
161
14,607
"Fury after viral video of James Talarico turned out to be manipulated" - Daily Mail #SmartNews l.smartnews.com/p-8FEvZHk4/5…
41
Karl Miran retweeted
I first met Amy Turner LaDow at HDSA’s EL-PFDD meeting with the FDA, where she courageously shared the heartbreaking story of losing her father to suicide and the staggering number of family members affected by Huntington’s disease. Amy’s family has endured an unimaginable generational burden. Twenty-eight family members across four generations have been affected by HD. She has lost three sisters to the disease, another sister is living with it, and Amy herself is gene-positive. You may remember Amy from her feature in The New York Times earlier this year, where she spoke about the FDA’s reversal regarding uniQure’s AMT-130 gene therapy and the hope that progress toward an approved treatment could bring families like hers. A fellow Midwesterner, Amy serves as President of the HDSA Indiana Chapter, an Advocacy Leader, and State Captain. Despite decades of profound personal loss, she continues fighting for her siblings, nieces, nephews, future generations, and our entire HD community. Huntington’s disease inflicts a uniquely devastating form of generational trauma. It is not enough that families must endure the progressive loss of those they love. Because HD is inherited, every child of an affected parent faces a 50% chance of inheriting the disease-causing gene. Families must navigate grief while confronting the possibility of the same fate for themselves, their children, and future generations. It is an extraordinary psychological burden layered upon an already devastating neurological disease. Behind every HD diagnosis is an entire family living with its consequences. We cannot separate the urgency of finding effective treatments from the mental health suffering this disease inflicts. Amy, thank you for sharing such a deeply personal story and for transforming unimaginable loss into unwavering advocacy. I am honored to stand alongside you in this fight. 💙💜 #HuntingtonsDisease #WorldMentalHealthDay #CureHD
8
37
2,276
Tracy Toscano hanging out with an Amherst College guy instagram.com/p/DeAO-4gvh_dL…
26
🚨 AMT-130 FOUR-YEAR DATA: Before you panic over “75% → 44%,” we need to talk about SURVIVOR BIAS. uniQure released its four-year AMT-130 data today. You're probably going to see headlines focusing on one number: At 48 months, high-dose AMT-130 showed 44% slowing of disease progression on cUHDRS compared with the updated ENROLL-HD natural-history control. That result was not statistically significant. But that is NOT the entire story. One of the most important numbers in today's release may actually be this: 53%. By four years, 53% of the matched ENROLL-HD control data were missing. And uniQure reports that the patients who stopped providing follow-up data were progressing materially faster than the patients who remained. Why does that matter? Imagine following 100 people with HD. Over time, the people progressing fastest become less likely to remain in an observational study — traveling gets harder, disability increases, participation becomes more burdensome, etc. Eventually, the people remaining in your dataset disproportionately represent those progressing more slowly. If you only look at who's left, it can make untreated HD appear to progress more slowly than it actually does. That's survivor bias — or, more specifically here, bias caused by non-random loss to follow-up. And when that group is your comparison for AMT-130, it matters enormously. Simple example: Treated patients decline 1 point. Untreated patients decline 4 points. ➡️ 75% slowing But imagine survivor bias makes the untreated group appear to decline only 2 points. The treated patients STILL decline exactly 1 point. Now the calculation says: ➡️ 50% slowing The treated patients didn't change. The comparison did. That's why saying simply, “AMT-130 dropped from 75% slowing to 44% slowing” leaves out an enormous part of the story. A few other important findings from today: 🔹 48 months — high dose cUHDRS: 44% slowing (p=0.144; not statistically significant) TFC: 61% slowing (nominal p=0.008) 🔹 When the SAME 48-month patients were compared with the previous ENROLL-HD control: cUHDRS: 53.5% slowing (nominal p=0.041) TFC: 68.3% slowing (nominal p=0.001) 🔹 Updated 36-month data — now 15 high-dose patients cUHDRS: 80% slowing TFC: 67% slowing And importantly, the four-year data continue to show a dose-response pattern, with the high-dose group declining less than the low-dose group. None of this means survivor bias automatically explains everything we're seeing at year four. We need to be careful about making that claim. But it DOES mean the 44% number cannot be interpreted in isolation. The percentage of “slowing” depends on BOTH sides of the equation: How the treated patients are doing AND how the comparison group is doing. If the faster-progressing people disappear from your natural-history dataset, your comparison group starts looking healthier — and the apparent treatment effect gets smaller. So please don't let a headline tell you that AMT-130 suddenly “stopped working.” The four-year data are more complicated than that. And for a progressive disease like Huntington's, understanding who is missing from the data can be just as important as understanding who is still there. #HuntingtonsDisease #AMT130 #TimeMatters
9
34
14
218
31,752
Karl Miran retweeted
$qure $clpt Interesting, completely different perspective from Tabrizi compared to Sung
𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞: Sarah Tabrizi of University College London discusses her experience as an investigator on UniQure's Huntington's Disease gene therapy, AMT-130. @OHRareDisease
13
2
35
13,821
Christina has a point. The HD, and the larger Rare Disease Community need to demonstrate how important real, legitimate science is to us. The lives of our people depend on the vital, fact-based scientific progress that has made America strong. Send Letters!! (it's easy)
HDSA is asking advocates to contact their U.S. House Representative and urge them to co-sponsor the bipartisan Congressional Review Act resolution led by Representatives Jake Auchincloss and Brian Fitzpatrick. Visit: votervoice.net/mobile/HDSA/C… #LetstalkaboutHD #HDAdvocacy #HDSA
5
548
Yesterday, I had the opportunity to meet with @FDA_KyleD and others with the @US_FDA, and I just want to say thank you. Thank you for taking the time to listen, to ask questions, and to engage in meaningful discussion about the lived experience of Huntington's disease and the realities our community faces every day. These conversations matter. They help build understanding, strengthen collaboration, and ensure that the patient voice remains an important part of the regulatory process. We don't expect everyone to have all the answers, but we deeply appreciate those who are willing to listen, learn, and work alongside us. I also appreciate the acknowledgment of something our community lives with every day: Our sense of urgency. Huntington's disease does not pause, and neither does its progression. Every day matters to the families living with this disease. I am grateful that our urgency was heard and that it continues to be part of the conversation as we work together toward safe and effective treatments. To everyone at the FDA who participated yesterday, thank you for your time, your openness, and your commitment to continuing the conversation. I am looking forward to what we can accomplish together as we continue working toward safe and effective treatments for the Huntington's disease community. Thank you for giving our community a seat at the table. Time matters, and we are grateful our voices - and our urgency - were heard. #TimeMatters #RareDisease #Huntingtonsdisease
We were so grateful to the FDA for bringing the collective #HuntingtonsDisease voice to this roundtable discussion. Thank you!
4
14
3
84
15,847
Karl Miran retweeted
Today’s lesson… Something you probably should NOT ask someone who is only 37 years old and was forced into retirement because of a terminal illness: “Are you enjoying retirement?” Not exactly a question I expected to hear. Especially from the person it came from. After all, I’m not at a typical retirement age. And I’m certainly not living a typical retirement. I’m fighting for my life every single day. Anyone who knows me knows being a police officer wasn’t just my job—it was part of who I was. It was my passion, my purpose, and a career I loved with my whole heart. ALS forced me into retirement at just 31 years old. It wasn’t my choice. It wasn’t my plan. It wasn’t my timeline. The truth is, there isn’t much I wouldn’t give for the chance to put the uniform back on, answer one more call, or simply have the life ALS stole from me. But over the years, I’ve realized something. God didn’t take away my purpose—He simply changed the way I live it. As a police officer, my calling was to serve and protect. Today, I still serve. It just looks different. Instead of responding to emergency calls, I respond to people who need hope. Instead of wearing a badge, I use my story. Instead of protecting my community in a police uniform, I fight every day to raise awareness for ALS, advocate for others, and remind people that joy and purpose can still exist in the hardest circumstances. So no, I’m not “enjoying retirement.” Because this isn’t retirement. This is a life I never would have chosen—but it’s also a life that still has purpose. The uniform is gone, but the mission never left. I share this because I know it can be difficult to know what to say to someone whose life has been changed by illness, especially when that illness has changed their outward appearance. You don’t have to have the perfect words. A simple, “How are you doing?” “I’m thinking about you.” “I’m praying for you.” Or even, “I’m glad to see you,” can mean far more than you realize. Sometimes the greatest gift you can give someone isn’t the right answer—it’s simply letting them know they are seen. #ALS #FightLikeAGirl
37
38
5
634
21,356
Karl Miran retweeted
$qure $clpt I have to say I find this pretty funny, Jeff Carroll one of the top hd researchers in the world was getting paid by wave life sciences to look into some stuff. He has also done work for Skyhawk. He has never worked with Uniqure. Jeff has HD, in said research he finds out that Uniqure has the best shot with treating amt 130 due to targeting of huntingtin 1a. Here he is, hoping he is completely wrong and was shocked what he found, has now said he and him family would take amt 130 today. I didn’t hear him say the other drugs he has actually worked with. If that doesn’t tell you something, I don’t know what will.
2
8
82
6,284
Karl Miran retweeted
The FDA’s greatest responsibility is not to protect patients from uncertainty; it is to help patients make informed choices in the face of devastating disease. For rare disease families, the risk of waiting is real. The Huntington’s disease community and rare disease communities everywhere understand the cost of delay. We live its consequences every day. Patients deserve a seat at the table. A truly patient-first @FDA must understand that urgency and scientific rigor are not opposing values; they are complementary. This is the leadership vision our rare disease community needs. Thank you, @HoumanHemmati
1
11
36
2,994
This is a wonderful OpEd from @houmanhemmati, who I greatly respect; even more so now. He continues to advocate for those of us with #raredisease. That matters so much. The parts that really spoke to me: "Adcomms should not just convene medical and scientific experts that aid FDA in assessing benefits and risks of a new treatment; when it comes to rare diseases, they must also include the patient viewpoint." "The work of adcomms is not just about science, but about humanity—a perspective that matters. That perspective is provided best by patients, their families and other patient advocates, but too often FDA adcomms are missing those voices. The decisions before advisory committees are rarely simple. Members must sometimes weigh incomplete data, uncertain outcomes and the hopes of patients with devastating diagnoses. The goal is always to protect public health while making promising treatments available to those who need them. When an adcomm evaluates a rare disease treatment, it should include experts with deep knowledge of that specific disorder and representatives from the patient community who live with its consequences every day. This is not a criticism of the dedicated scientists and physicians who currently serve on these panels but a recognition that rare diseases present unique challenges that often do not fit neatly into traditional regulatory frameworks. For families confronting progressive, life-limiting illnesses, time is not an abstract concept as every month can mean the loss of function, cognition or life itself. This can be difficult to fully appreciate without direct experience treating patients with the disease under review. When adcomms debate risk associated with approving a treatment on an accelerated timeline, patients and families bring a perspective that no dataset can provide—an understanding of the risk of waiting for treatment. This is particularly important because risk tolerance is different in rare diseases, especially for the approximately 15 million American children living with rare conditions, 30% of whom will not even live to age five. The goal should be to evaluate evidence using approaches that reflect the realities of rare disease populations rather than force those populations into frameworks designed for entirely different circumstances. Reforms should not weaken scientific standards but strengthen the quality of decision-making by ensuring that the right experts are in the room—including patients themselves—and that the realities of rare disease are fully understood. America has long been the world’s leader in medical innovation. We can continue that tradition by modernizing how FDA adcomms evaluate therapies for rare diseases while ensuring patients are partners in the process. Policymakers and regulators should be encouraged to embrace this common-sense approach that empowers patients and physicians to make informed treatment decisions without dedicated and well-meaning government officials unnecessarily limiting those choices. "As physician and entrepreneur @PeterDiamandis recently noted on X, “The most unethical thing in medicine is the patient who died waiting for a treatment that existed but wasn’t approved yet.” 💪💙 #huntingtonsdisease #rarelivesontheline #ActWithUrgency #ActWithIntegrity @US_FDA @FDA_KyleD @WhiteHouse
3
8
1
40
4,058
Christina sums up what many of us experience when we are together. And hooray for the researchers giving us all hope.
I spent the last few days surrounded by everything Huntington’s disease. That might sound heartbreaking. In many ways, it is. But it is also where the burden becomes a little lighter. #HDSAConvention brings together people who truly understand what it means to live with Huntington’s disease. We understand the uncertainty of a 50/50 genetic inheritance. We understand children becoming caregivers, siblings lifting each other up, spouses becoming caregivers, and loved ones standing beside us through every stage of this disease. No one carries HD alone. This year, I left with hope. Hope because of the incredible scientific progress being made. Hope because researchers, clinicians, advocates, industry, and the @FDA are working toward a future where Huntington’s disease can be treated before symptoms begin and where we can measure success without waiting for irreversible decline. The convention ended with the candlelighting ceremony. Nearly 800 glowing lights filled the room, each one representing someone we have lost, someone still fighting, or someone whose future we are determined to change. It was a beautiful reminder of why this work matters. I was especially proud of Michigan this weekend. Our community was honored with three national HDSA awards, including HDSA Chapter of the Year, a Youth/Juvenile Huntington’s Disease Award, and the Marjorie Guthrie Award presented to our former chapter president. Those honors reflect the extraordinary heart, dedication, and leadership of Michigan’s HD community. Thank you, @HDSA, for creating a place where hope grows, friendships are formed, and families leave believing that a different future is possible. Together, we are changing the story of Huntington’s disease. 💙💜🧬🕯️ #HDSAConvention #HDSA #HuntingtonsDisease #HDResearch #RareDisease
1
3
134
Karl Miran retweeted
First off, this is an incredible day for HD patients and families. A generational, devastating, slow-bleed disease with no disease-modifying therapy now has the first ever GT in sight in the US. The rollercoaster has been real, the wait has been brutal, and today’s FDA re-alignment is long overdue. These families deserve this. I’m genuinely happy for every one of them. From a capital markets perspective, $qure is incredibly undervalued at current levels. The 3-year data that was always sufficient is now formally accepted as BLA-grade. No sham surgery — standard-of-care confirmatory control instead. RMAT added to Breakthrough and Fast Track. UK MHRA MAA filing Q3 2026, with the brand new MHRA-FDA liaison programme announced yesterday providing direct transatlantic alignment. Gulf states real. AMT-260 readout Friday now worth more from a platform validation standpoint. And Sung’s recent public comments about his patient cohort suggest the 4-year data will be compelling. Sell side will take time to update models and they need to answer “what is the US worth, what is the UK worth, what does early label access look like.” But at $81 with Prasad at CBER, no MHRA movement, and none of today’s catalysts, the market found fair value. Today’s setup is materially stronger on every dimension. The models will catch up. The compounder awakes. $qure
17
43
6
241
20,500
Miles to go, but still positive news. Will be looking for signs of a genuine sea change.
$qure $clpt comments from the Cure Sanfilippo Foundation perspective on the closed door meeting. The fact that the new commissioner came in and immediately prioritized speaking directly with rare disease advocates shows a positive shift at the agency. As Commissioner Diamantas said, "This represents a reset and a recommitment to rare disease." Agency leaders spoke to the challenges that the rare disease community has experienced and expressed a desire to get things back on track. They also discussed their shared desire for regulatory adaptability, with a focus on applying strategies that are best suited to each situation rather than a one-size-fits-all approach, as well as recognition that patient-experience data provides a meaningful source of evidence.
1
5
611